Literature DB >> 3728534

Prevalence and mechanisms of aminoglycoside resistance. A ten-year study.

I Phillips, A King, K Shannon.   

Abstract

Aminoglycoside resistance was monitored at St. Thomas' Hospital from 1975 to 1984. Gentamicin resistance had appeared in a number of species by 1975, but remained rare (less than 1 percent of isolates) in Escherichia coli throughout the study period. Gentamicin-resistant Klebsielleae had become fairly common (8 percent of isolates) by 1977, but little change has subsequently occurred in their frequency of isolation. Serratia species are not frequently isolated; gentamicin resistance in these organisms was not observed until 1979. Since then, 10 to 20 percent of isolates have been found to be resistant. Except for Providencia, most isolates of which were gentamicin-resistant, less than 5 percent of the Enterobacteriaceae isolated were found to be resistant to gentamicin during the 10-year period. Throughout the study, approximately 5 percent of the Pseudomonas aeruginosa isolates were resistant to gentamicin. Less than 5 percent of the isolates of Acinetobacter were resistant to gentamicin before 1979, at which time 40 percent were found to be resistant; subsequently, gentamicin resistance among these organisms has become somewhat less common. On the whole, tobramycin resistance has mirrored gentamicin resistance. However, before 1979, most gentamicin-resistant Klebsielleae isolates had retained susceptibility to tobramycin, as had most gentamicin-resistant isolates of Acinetobacter and P. aeruginosa. Amikacin resistance has remained very unusual in all organisms, apart from non-aeruginosa Pseudomonas species. Until 1977, nearly all the resistance among Enterobacteriaceae was attributable to AAC(3)-I, except for that caused by AAC(2') production in Providencia and the non-enzymatic resistance observed in E. coli. However, more recently, AAC(3)-II and AAD(2'') have become the most common mechanisms of resistance. The resistance of most gentamicin-resistant isolates of P. aeruginosa from 1974 to 1977 was attributable to non-enzymatic mechanisms; subsequently, such resistance was more often caused by AAC(3)-I, AAC(6'), or AAD(2''). Gentamicin resistance first appeared in Staphylococcus aureus in 1976, after which about 1 to 2 percent of the isolates from hospitalized patients were found to be resistant, mostly because of production of AAC(6') and APH(2'').

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3728534     DOI: 10.1016/0002-9343(86)90479-1

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  6 in total

Review 1.  Aminoglycoside resistance in Pseudomonas aeruginosa.

Authors:  Keith Poole
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

2.  In vitro susceptibility to aminoglycoside antibiotics in blood and urine isolates consecutively collected in twenty-nine European laboratories. European Study Group on Antibiotic Resistance.

Authors: 
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

3.  Characterization of a Pseudomonas aeruginosa efflux pump contributing to aminoglycoside impermeability.

Authors:  S Westbrock-Wadman; D R Sherman; M J Hickey; S N Coulter; Y Q Zhu; P Warrener; L Y Nguyen; R M Shawar; K R Folger; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1999-12       Impact factor: 5.191

4.  Different aminoglycoside-resistant phenotypes in a rabbit Staphylococcus aureus endocarditis infection model.

Authors:  N Asseray; J Caillon; N Roux; C Jacqueline; R Bismuth; M F Kergueris; G Potel; D Bugnon
Journal:  Antimicrob Agents Chemother       Date:  2002-05       Impact factor: 5.191

5.  Aminoglycoside-resistance mechanisms in multidrug-resistant Staphylococcus aureus clinical isolates.

Authors:  R Kelmani Chandrakanth; S Raju; S A Patil
Journal:  Curr Microbiol       Date:  2008-03-05       Impact factor: 2.188

6.  The prevalence of aminoglycoside-modifying enzyme genes (aac (6')-I, aac (6')-II, ant (2")-I, aph (3')-VI) in Pseudomonas aeruginosa.

Authors:  Farzam Vaziri; Shahin Najar Peerayeh; Qorban Behzadian Nejad; Abbas Farhadian
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.